Generic drug manufacturers face significant challenges despite playing a key role in lowering healthcare costs. Intense competition quickly drives down prices and compresses margins, while consolidated buyers such as large pharmacy chains, wholesalers, and PBMs hold strong negotiating power. Companies must also meet strict regulatory requirements from agencies like the U.S. Food and Drug Administration, manage costly development and patent litigation processes, and maintain complex global supply chains that often rely on API production in countries such as India and China. Combined with policy uncertainty and the financial strain of producing low-margin essential medicines, these pressures can lead to market exits and drug shortages, making long-term sustainability challenging.

Poll results indicate that rising costs and pricing pressures are viewed as the greatest challenge for generic manufacturers, receiving 50% of responses. Increased rebates from brand manufacturers was the second most-cited concern at 38%, suggesting that competitive contracting dynamics continue to strain the generic marketplace. Complex supply chains received 12% of responses, while other potential challenges, including market saturation, evolving regulatory requirements, managing shortages, and inconsistent quality, did not receive any votes, highlighting that financial pressures dominate industry concerns.

Which is the greatest challenge for generic manufacturers?

Market saturation: 0%

Rising costs / Pricing pressures: 50%

Complex supply chains: 12%

Evolving regulatory requirements: 0%

Managing shortages: 0%

Inconsistent quality: 0%

Increased rebates from brand manufacturers: 38%